Gainers

• Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million.
• Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 16.56% to $2.54. The market value of their outstanding shares is at $5.2 million.
• Cryo-Cell International (AMEX:CCEL) shares moved upwards by 15.89% to $4.23. The market value of their outstanding shares is at $33.4 million.
• CytoSorbents (NASDAQ:CTSO) shares moved upwards by 14.37% to $3.5. The market value of their outstanding shares is at $9.7 million.
• Actuate Therapeutics (NASDAQ:ACTU) stock moved upwards by 12.3% to $0.56. The company's market cap stands at $10.4 million.
• ALX Oncology Holdings (NASDAQ:ALXO) stock moved upwards by 11.0% to $1.11. The market value of their outstanding shares is at $120.3 million.

Losers

• MDxHealth (NASDAQ:MDXH) stock decreased by 63.5% to $0.22 during Friday's regular session. The company's market cap stands at $60.2 million.
• Fractyl Health (NASDAQ:GUTS) shares declined by 58.39% to $1.73. The market value of their outstanding shares is at $54.1 million.
• Curis (NASDAQ:CRIS) stock declined by 21.26% to $0.4. The company's market cap stands at $1.4 million.
• Jaguar Health (NASDAQ:JAGX) shares fell 19.4% to $3.7. The company's market cap stands at $2.1 million.
• Advanced Biomed (NASDAQ:ADVB) shares decreased by 18.04% to $4.0. The market value of their outstanding shares is at $8.4 million. As per the press release, Q4 earnings came out 3 days ago.
• Pomdoctor (NASDAQ:POM) stock declined by 18.01% to $0.58. The market value of their outstanding shares is at $5.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.